CONTRA EL CÁNCER, MÁS VERDURA Y MENOS CARNE, REFRESCOS Y ALCOHOL . Post by Celtia .

JUAN REVENGA FRAUCA .

23 JUL 2018 .

El Fondo Mundial para la Investigación del Cáncer y el Instituto Estadounidense para la Investigación del Cáncer acaban de publicar su tercer informe de expertos, en el que se resume toda la evidencia sobre cómo la alimentación y la actividad física pueden llegar a influir en los procesos biológicos que sustentan el desarrollo y la progresión de esta enfermedad. Esto es lo que se sabe y lo demás son pavadas: al igual que en los dos informes anteriores, el Reiki, el extracto de azafrán, el germen de trigo verde y otros despropósitos por el estilo brillan por su ausencia. Y no es precisamente por falta de espacio, si en algo destaca este informe respecto a los anteriores es por su extensión: completo consta de cerca de 12.000 páginas (se puede descargar comprimido en este enlace) y su versión resumida, cerca de 100 (aquí para descargar). La pena es que, al menos de momento -y a diferencia con el 2º informe-, no haya material en español. ...

Yondelis Combi Inmunoterapia . Soft Tissue Sarcoma: Nivolumab ( Bristol Myers ) With Trabectedin Is Safe and Clinically Active .

Link en relación: XHJDFG


Nivolumab con Yondelis son Seguros y Clinicamente Activos en STS .

Trabectedin, an alkylating agent, removes tumor growth–promoting M2 macrophages, leading to more effective natural killer T cell activity.

The following article features coverage from the Connective Tissue Oncology Society (CTOS) in Maui, Hawaii. Click here to read more of Cancer Therapy Advisor's conference coverage.

Trabectedin and nivolumab are a promising combination for patients with advanced soft tissue sarcoma, according to an oral presentation at the Connective Tissue Oncology Society (CTOS) 2017 Annual Meeting.1

Trabectedin, an alkylating agent, removes tumor growth–promoting M2 macrophages, leading to more effective natural killer T cell activity. For this retrospective study, researchers evaluated whether intravenous nivolumab, a PD-1 inhibitor, is safe and effective when given with trabectedin.

Twenty patients included in the study had metastatic disease. Of those, 8 had undifferentiated pleomorphic liposarcoma, 4 had leiomyosarcoma, 3 had synovial sarcoma, 4 had myxoid liposarcoma, and 1 had chondrosarcoma; the median number of previous chemotherapy lines was 4.

Of the 13 patients followed for at least 6 months, 3 had a partial response, 7 had stable disease, and 3 had progressive disease, representing a disease control rate of 76.9%. Median progression-free survival was 7.8 months; median overall survival was 8.4 months.

The presenter noted that the median progression-free survival was 3.6 months longer than that observed with trabectedin alone.

Grade 3 adverse events included anemia, fatigue, decreased platelet count, decreased granulocyte count, and increased creatine kinase, though none of these were observed in more than 2 patients.

The authors concluded that “the data suggest that paired administration of trabectedin and nivolumab is safe, and that this chemo-/immuno-therapy approach has synergistic activity.”

A study is being planned in which trabectedin will be given in conjunction with nivolumab and ipilimumab, a CTLA-4 inhibitor.